BioWorld

Sep. 5, 2008

Prometic Inks Four-Product Deal with Abraxis Worth up to $295M

ProMetic Life Sciences Inc. entered a potential $295 million licensing agreement with Abraxis BioScience to develop four products targeting undisclosed underserved medical conditions on a worldwide basis, excluding China and Taiwan. (BioWorld Today) Read More

FDA Orders Histoplasmosis Warnings for TNF Blockers

Genomic Study Has Sobering Implications for Cancer Drugs

Ablynx Signs Merck to Potential $481M Nanobodies Partnership

As Provigil Sales Fall Short, Cephalon, Takeda Part Ways

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...